JP2005533825A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533825A5
JP2005533825A5 JP2004518103A JP2004518103A JP2005533825A5 JP 2005533825 A5 JP2005533825 A5 JP 2005533825A5 JP 2004518103 A JP2004518103 A JP 2004518103A JP 2004518103 A JP2004518103 A JP 2004518103A JP 2005533825 A5 JP2005533825 A5 JP 2005533825A5
Authority
JP
Japan
Prior art keywords
disease
halo
compound
compound according
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004518103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533825A (ja
JP4616643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/020557 external-priority patent/WO2004002961A1/en
Publication of JP2005533825A publication Critical patent/JP2005533825A/ja
Publication of JP2005533825A5 publication Critical patent/JP2005533825A5/ja
Application granted granted Critical
Publication of JP4616643B2 publication Critical patent/JP4616643B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004518103A 2002-06-28 2003-06-27 カスパーゼインヒビターおよびそれらの用途 Expired - Fee Related JP4616643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39259202P 2002-06-28 2002-06-28
US43507302P 2002-12-20 2002-12-20
PCT/US2003/020557 WO2004002961A1 (en) 2002-06-28 2003-06-27 Caspase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010023632A Division JP2010143942A (ja) 2002-06-28 2010-02-04 カスパーゼインヒビターおよびそれらの用途

Publications (3)

Publication Number Publication Date
JP2005533825A JP2005533825A (ja) 2005-11-10
JP2005533825A5 true JP2005533825A5 (cg-RX-API-DMAC7.html) 2006-08-03
JP4616643B2 JP4616643B2 (ja) 2011-01-19

Family

ID=30003264

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004518103A Expired - Fee Related JP4616643B2 (ja) 2002-06-28 2003-06-27 カスパーゼインヒビターおよびそれらの用途
JP2010023632A Pending JP2010143942A (ja) 2002-06-28 2010-02-04 カスパーゼインヒビターおよびそれらの用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010023632A Pending JP2010143942A (ja) 2002-06-28 2010-02-04 カスパーゼインヒビターおよびそれらの用途

Country Status (19)

Country Link
US (2) US7553852B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539701A1 (cg-RX-API-DMAC7.html)
JP (2) JP4616643B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050013260A (cg-RX-API-DMAC7.html)
CN (1) CN100503572C (cg-RX-API-DMAC7.html)
AR (1) AR040350A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003248758A1 (cg-RX-API-DMAC7.html)
BR (1) BR0312232A (cg-RX-API-DMAC7.html)
CA (1) CA2493646A1 (cg-RX-API-DMAC7.html)
IL (1) IL165986A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05000069A (cg-RX-API-DMAC7.html)
NO (1) NO20050851L (cg-RX-API-DMAC7.html)
NZ (1) NZ537807A (cg-RX-API-DMAC7.html)
PE (1) PE20040728A1 (cg-RX-API-DMAC7.html)
PL (1) PL374598A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005102094A (cg-RX-API-DMAC7.html)
TW (1) TW200404783A (cg-RX-API-DMAC7.html)
UY (1) UY27872A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004002961A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) * 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
JP5001150B2 (ja) * 2004-06-08 2012-08-15 ファミリーズ オブ スパイナル マスキュラー アトロフィー 脊髄性筋萎縮症のための2,4−ジアミノキナゾリン
EP1784390A2 (en) * 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
ES2312012T3 (es) * 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
WO2006057961A1 (en) * 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
AU2006254936A1 (en) * 2005-06-07 2006-12-14 The Trustees Of The University Of Pennesylvania Inhibitors of the alpha2beta1/GPIa-IIa integrin
KR20080038369A (ko) * 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
WO2007027742A2 (en) * 2005-08-31 2007-03-08 The Trustees Of The University Of Pennsylvania SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
CA2659376C (en) 2006-08-01 2014-10-14 Jasbir Singh 2,4-diaminoquinazolines for spinal muscular atrophy
EP2066640B1 (en) * 2006-09-11 2011-09-07 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
MX357834B (es) * 2012-01-26 2018-07-26 Ptc Therapeutics Inc Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
AU2020231396B2 (en) * 2019-03-07 2025-03-20 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
KR102670554B1 (ko) * 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DD232699A1 (de) * 1983-11-18 1986-02-05 Adw Ddr Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
BR9712987A (pt) 1996-10-11 2000-04-18 Warner Lambert Co Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
CA2268098A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
RU2263109C2 (ru) 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
DE60131160T2 (de) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
JP2005509028A (ja) * 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
EP1485107A1 (en) * 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (en) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2006057961A1 (en) 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors

Similar Documents

Publication Publication Date Title
JP2003535865A5 (cg-RX-API-DMAC7.html)
JP2006513220A5 (cg-RX-API-DMAC7.html)
RU2005102094A (ru) Ингибиторы каспазы и их применение
JP2003534325A5 (cg-RX-API-DMAC7.html)
RU2005140657A (ru) Ингибиторы каспаз и их применение
CN101679352A (zh) 制备农药苯甲酰胺化合物的方法
JP2003506389A5 (cg-RX-API-DMAC7.html)
KR20200120177A (ko) 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1h-피롤-3-일]-n-메틸메탄아민의 신규염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
JP2007525503A5 (cg-RX-API-DMAC7.html)
JP2002514649A (ja) エポチロン誘導体、それらの製造方法、並びにそれらの使用
JP2010523647A (ja) 安定した無水結晶形ドセタキセル及びその製造方法
DE69128477T2 (de) Benzopyranderivat
JP2009502922A5 (cg-RX-API-DMAC7.html)
RU2007123615A (ru) Производные 3-[2-(3-ациламино-2-оксо-2н-пиридин-1-ил)-ацетиламино]-4-оксо-пентановой кислоты и их применение в качестве ингибиторов каспазы
JPH03193799A (ja) 3―(l―ピログルタミル)―l―チアゾリジン―4―カルボン酸およびその誘導体の製造方法
US7638634B2 (en) Amorphous esomeprazole hydrate
CN101939289A (zh) 用于制备伏立诺他的新方法
JP3652713B2 (ja) 粒径の改善されたスピログリコールの製造方法
WO2016075588A1 (en) Stable amorphous daclatasvir dihydrochloride
CA2551501A1 (en) Tolterodine, compositions and uses thereof, and preparation of the same
CA2451979A1 (en) Novel modifications of the trometamol salt of r-thioctic acid and method for producing the same
CN100509788C (zh) 神经降压素活性的2,3-二芳基-吡唑烷衍生物
KR101012135B1 (ko) 발사르탄 메틸 에스테르의 제조방법
CA2508341A1 (en) Processes for preparing quinolonecarboxylate derivatives
KR102888694B1 (ko) 알킬-d-알라니네이트의 제조방법